WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H412482
CAS#: 40180-04-9
Description: Ticrynafen is a novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.
Hodoodo Cat#: H412482
Name: Ticrynafen
CAS#: 40180-04-9
Chemical Formula: C13H8Cl2O4S
Exact Mass: 329.95
Molecular Weight: 331.160
Elemental Analysis: C, 47.15; H, 2.44; Cl, 21.41; O, 19.32; S, 9.68
Synonym: Ticrynafen; ANP3624; ANP-3624; ANP 3624; Tienilic Acid
IUPAC/Chemical Name: 2-(2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid
InChi Key: AGHANLSBXUWXTB-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)
SMILES Code: OC(COc1c(Cl)c(Cl)c(C(c2sccc2)=O)cc1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 331.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Murray TG, Brown S, Dubb JW, Hwang BY, Stote RM. Ticrynafen in anephric patients: effects on uric acid and pharmacokinetics. Clin Pharmacol Ther. 1980 May;27(5):686-9. doi: 10.1038/clpt.1980.97. PMID: 7371365.
2: Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. N Engl J Med. 1979 Aug 9;301(6):293-7. doi: 10.1056/NEJM197908093010602. PMID: 377081.
3: Barclay WR. Ticrynafen's withdrawal from the market. JAMA. 1980 Feb 22-29;243(8):771. PMID: 7351824.
4: Stote RM, Dubb JW, Familiar RG, Alexander F. Ticrynafen, a uricosuric antihypertensive diuretic. Clin Pharmacol Ther. 1978 Apr;23(4):456-60. doi: 10.1002/cpt1978234456. PMID: 630794.
5: Maass AR, Snow IB, Beg M, Stote RM. Pharmacokinetics and mode of action of tienilic acid. Clin Exp Hypertens A. 1982;4(1-2):139-60. doi: 10.3109/10641968209061581. PMID: 7074982.
6: Preusch PC, Suttie JW. Mechanism of ticrynafen potentiation of coumarin anticoagulant action. Biochem Pharmacol. 1983 Aug 15;32(16):2393-8. doi: 10.1016/0006-2952(83)90681-0. PMID: 6615542.
7: Croft MA, Wang RF, Podos SM, Neufeld AH, Kaufman PL. Effect of ticrynafen on aqueous humor dynamics in monkeys. Arch Ophthalmol. 1998 Nov;116(11):1481-8. doi: 10.1001/archopht.116.11.1481. PMID: 9823350.
8: Nemati M, Kyle MC, Freis ED. Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent. JAMA. 1977 Feb 14;237(7):652-6. PMID: 319271.
9: Snow IB, Maass AR. Renal sites of natriuretic and uricosuric activity of ticrynafen in the mongrel dog. Nephron. 1979;23 Suppl 1:15-20. doi: 10.1159/000181662. PMID: 471147.
10: Emmerson BT, Renshaw PJ, Ravenscroft PJ, Denham I, Schey S. Ticrynafen and hydrochlorothiazide. A comparison in hypertensive patients with renal impairment. Eur J Clin Pharmacol. 1982;22(3):203-6. doi: 10.1007/BF00545215. PMID: 7049708.
